医学
肺癌
恶性胸腔积液
危险系数
化疗
内科学
临床终点
置信区间
外科
胸腔积液
回顾性队列研究
比例危险模型
倾向得分匹配
队列
队列研究
肺
肿瘤科
癌症
性能状态
不利影响
呼吸道疾病
胸膜成形术
生存分析
胸膜疾病
作者
Chang Qi,Yalun Li,Ran Wang,Yi Xiang,Hailong Wei,Yong Cao,Ling Peng,Changyi Li,宋慧芳,Hui Ren,Li Jiang,Ran Li,Jia Zeng,Minjiang Chen,Dehe Chen,Yi Zeng,Xueling Wu,Qinghua Liu,Yi Zhang,Huai Liao
标识
DOI:10.1177/17534666261499218
摘要
Background Intrapleural anticancer therapies are increasingly used in clinical practice; however, their additional benefit over indwelling pleural catheter (IPC) alone and the optimal intrapleural strategy remain uncertain. Platinum-based chemotherapy is a common intrapleural approach. Objective This study evaluated the efficacy and safety of IPC combined with intrapleural platinum-based chemotherapy in lung cancer patients with symptomatic malignant pleural effusion (MPE). Design A multicenter retrospective real-world cohort study. Methods Patients with symptomatic MPE from 27 tertiary care centers received IPC alone, IPC combined with intrapleural platinum-based chemotherapy, or IPC combined with other intrapleural agents. The primary endpoint was progression-free survival of MPE (MPE PFS); secondary endpoints were overall survival (OS), the objective response rate of MPE at 8 weeks (8-week MPE ORR), and safety. Propensity score matching (PSM) was performed as a sensitivity analysis. Results Of the 391 patients, 229 received IPC alone, 93 received IPC combined with intrapleural platinum-based chemotherapy, and 69 received other intrapleural agents. Among the evaluated strategies, platinum-based chemotherapy was associated with the longest MPE PFS and the highest 8-week MPE ORR (87.1%). Compared with IPC alone, the hazard ratios (HRs) for MPE PFS and OS were 0.64 (95% confidence interval [CI], 0.46 -0.88; P = 0.006) and 0.69 (95% CI, 0.50 -0.97; P = 0.035), respectively. Multivariate Cox regression analysis identified intrapleural platinum-based chemotherapy as an independent predictor of prolonged MPE PFS, but not OS. The associations with MPE PFS and 8-week MPE ORR findings remained significant after PSM, whereas OS did not differ. Within the platinum-based chemotherapy group, regimens that included antiangiogenesis or interleukin-2 did not confer additional benefit over platinum monotherapy. Adverse event rates were comparable between groups (11.3% vs. 17.2%; P = 0.219). Conclusions IPC combined with intrapleural platinum-based chemotherapy was associated with improved pleural control and acceptable safety.
科研通智能强力驱动
Strongly Powered by AbleSci AI